Please use this identifier to cite or link to this item:
Title: Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?
Author: Izquierdo, Conchita
Salleras i Sanmartí, Lluís
Domínguez García, Àngela
Keywords: Farmacologia
Pneumònia adquirida a la comunitat
Community-acquired pneumonia
Issue Date: 2012
Publisher: Transworld Research Network
Abstract: Although bacteremic pneumococcal pneumonia is the most severe form of pneumonia, non-bacteremic forms are much more frequent. Laboratory methods for the diagnosis of nonbacteremic pneumococcal pneumonia have a low sensitivity and specificity, and therefore all-cause pneumonia has been proposed as a suitable outcome to evaluate vaccination effectiveness. This work reviews the epidemiology of community-acquired pneumonia (CAP) and evaluates the effectiveness of the 3-valent pneumococcal polysaccharide vaccine (PPV-23) in preventing CAP requiring hospitalization in people aged ≥65 years. We performed a case-control study in patients aged ≥65 years admitted through the emergency department who presented with clinical signs and symptoms compatible with pneumonia. We included 489 cases and 1,467 controls and it was obtained a vaccine efectiveness of 23.6 (0.9-41.0). Our results suggest that PPV-23 vaccination is effective and reduces hospital admissions due to pneumonia in the elderly, strengthening the rationale for vaccination programmes in this age group.
Note: Podeu consultar el llibre complet a:
Note: Reproducció del capítol 5 del llibre publicat a:
It is part of: Recent Advances in Pharmaceutical Sciences II, 2012, Editor: Diego Muñoz-Torrero, Diego Haro and Joan Vallès, Chapter 5, p. 69-87.
Appears in Collections:Llibres / Capítols de llibre (Medicina)

Files in This Item:
File Description SizeFormat 
RAPS_II_Ch5.pdf431 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.